MedWatch

Employment researcher: Novo Nordisk salary advances are part of retention strategy

In a tense global struggle to find skilled labor, Novo Nordisk has signaled it is prepared to go a little further to retain and attract new employees, says a Copenhagen University researcher.

Novo Nordisk's employees will have their remuneration regulated at the end of the year instead of having to wait until Q1 or Q2, 2023 | Photo: Novo Nordisk / PR

Novo Nordisk moving up wage increases for 50,000 employees should also be viewed as an attempt at profiling the company in the competition for highly qualified labor, of which the industry reports a shortage, says Søren Kaj Andersen, head of the Danish Employment Relations Research Center, FAOS, at the University of Copenhagen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs